Clinical Trials Browser

Withdrawn × Chromosome 17 deletion × ibrutinib × Clear all

NCT03943342 2021-11-05

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell